Genus Capital Management Inc. Purchases New Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Genus Capital Management Inc. bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,600 shares of the medical equipment provider's stock, valued at approximately $742,000.

Several other institutional investors also recently bought and sold shares of LNTH. Summit Securities Group LLC purchased a new stake in shares of Lantheus during the 4th quarter valued at approximately $37,000. UMB Bank n.a. grew its stake in shares of Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after acquiring an additional 381 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after purchasing an additional 633 shares in the last quarter. 1620 Investment Advisors Inc. acquired a new position in shares of Lantheus during the fourth quarter worth $125,000. Finally, GAMMA Investing LLC grew its stake in shares of Lantheus by 29.3% during the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock worth $128,000 after purchasing an additional 298 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Down 2.2%

Shares of Lantheus stock traded down $1.80 during trading on Tuesday, reaching $81.26. The company had a trading volume of 764,453 shares, compared to its average volume of 972,772. The company has a market cap of $5.62 billion, a price-to-earnings ratio of 23.09 and a beta of 0.12. The firm's fifty day moving average is $80.26 and its 200-day moving average is $89.91. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. Lantheus Holdings, Inc. has a fifty-two week low of $73.11 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.69 EPS. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on LNTH. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley cut their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $131.20.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.00% of the stock is currently owned by company insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.